Skip to content
  • Home
  • Book Bag: 0 items (Full)
    • English
    • 日本語
    • 中文(简体)
    • 中文(繁體)
    • اللغة العربية
  • About
Advanced
  • Prognostic relevance of molecu...
  • Cite this
  • Text this
  • Print
  • Export Record
    • Export to RefWorks
    • Export to EndNoteWeb
    • Export to EndNote
  • Add to Book Bag Remove from Book Bag
  • Permanent link

Prognostic relevance of molecular measurable residual disease detection in AML with mutated CEBPA

Bibliographic Details
Published in:HemaSphere
Main Authors: Christian M. Vonk, Emma L. Boertjes, Francois G. Kavelaars, Melissa Rijken, Jolinda M. L. Konijnenburg, Roxanne E. Cromwell, Bob Löwenberg, Tim Grob, Peter J. M. Valk
Format: Article
Language:English
Published: Wiley 2024-08-01
Online Access:https://doi.org/10.1002/hem3.141
  • Holdings
  • Description
  • Similar Items
  • Staff View

Internet

https://doi.org/10.1002/hem3.141

Similar Items

  • Advantages of a genomic DNA-based next-generation sequencing assay for detection of mutant NPM1 measurable residual disease in AML
    by: Christian M. Vonk, et al.
    Published: (2025-03-01)
  • Utility of IDH1/2 mutations as biomarkers for detection of measurable residual disease in acute myeloid leukemia
    by: Emma L. Boertjes, et al.
    Published: (2025-10-01)
  • P404: PROGNOSTIC IMPACT OF CEBPA-MUTATIONAL SUBGROUPS IN ADULT AML – RESULTS OF A LARGE METAANALYSIS IN MORE THAN 1000 CEBPA-MUTANT PATIENTS
    by: J.-A. Georgi, et al.
    Published: (2022-06-01)
  • Impact of baseline genetic profile and treatment on outcome and hematological toxicity in CEBPA-mutated AML
    by: Francesco Mannelli, et al.
    Published: (2025-03-01)
  • S119: CEBPA AND TET2 MUTATIONS COOPERATE TO INDUCE AGGRESSIVE AML VIA GATA-2 DOWNREGULATION
    by: E. Heyes, et al.
    Published: (2022-06-01)

Search Options

  • Search History
  • Advanced Search

Find More

  • Browse the Catalog
  • Browse Alphabetically
  • Explore Channels
  • Course Reserves
  • New Items

Need Help?

  • Search Tips
  • Ask a Librarian
  • FAQs